
Jeppe Sturis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2365022/publications.pdf Version: 2024-02-01



IFDDF STUDIS

#	Article	IF	CITATIONS
1	Non-Insulin-Dependent Diabetes Mellitus — A Genetically Programmed Failure of the Beta Cell to Compensate for Insulin Resistance. New England Journal of Medicine, 1996, 334, 777-783.	27.0	542
2	One Week's Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and Â- and Â-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes. Diabetes, 2004, 53, 1187-1194.	0.6	417
3	Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus Journal of Clinical Investigation, 1995, 96, 520-527.	8.2	366
4	Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus Journal of Clinical Endocrinology and Metabolism, 1993, 77, 1287-1293.	3.6	282
5	Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes. Diabetes, 2002, 51, 424-429.	0.6	275
6	Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects. Diabetes Care, 2002, 25, 1398-1404.	8.6	272
7	Effects of Metformin on Insulin Secretion, Insulin Action, and Ovarian Steroidogenesis in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 524-530.	3.6	260
8	Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations Journal of Clinical Investigation, 1994, 93, 1120-1130.	8.2	254
9	Altered Insulin Secretory Responses to Glucose in Diabetic and Nondiabetic Subjects With Mutations in the Diabetes Susceptibility Gene MODY3 on Chromosome 12. Diabetes, 1996, 45, 1503-1510.	0.6	245
10	The GLP-1 Derivative NN2211 Restores Â-Cell Sensitivity to Glucose in Type 2 Diabetic Patients After a Single Dose. Diabetes, 2003, 52, 1786-1791.	0.6	205
11	Small-molecule agonists for the glucagon-like peptide 1 receptor. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 937-942.	7.1	204
12	GLP-1 derivative liraglutide in rats with β -cell deficiencies: influence of metabolic state on β -cell mass dynamics. British Journal of Pharmacology, 2003, 140, 123-132.	5.4	179
13	Ultradian Oscillations of Leptin Secretion in Humans. Biochemical and Biophysical Research Communications, 1996, 228, 733-738.	2.1	176
14	Modeling the Insulin–Glucose Feedback System: The Significance of Pulsatile Insulin Secretion. Journal of Theoretical Biology, 2000, 207, 361-375.	1.7	176
15	Defects in Insulin Secretion and Action in Women With a History of Gestational Diabetes. Diabetes, 1995, 44, 506-512.	0.6	149
16	Glucose- and Interleukin-1Â-Induced Â-Cell Apoptosis Requires Ca2+ Influx and Extracellular Signal-Regulated Kinase (ERK) 1/2 Activation and Is Prevented by a Sulfonylurea Receptor 1/Inwardly Rectifying K+ Channel 6.2 (SUR/Kir6.2) Selective Potassium Channel Opener in Human Islets. Diabetes, 2004, 53, 1706-1713.	0.6	149
17	Novel Tricyclic-α-alkyloxyphenylpropionic Acids:  Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity. Journal of Medicinal Chemistry, 2002, 45, 789-804.	6.4	139
18	A novel high-affinity peptide antagonist to the insulin receptor. Biochemical and Biophysical Research Communications, 2008, 376, 380-383.	2.1	136

JEPPE STURIS

#	Article	IF	CITATIONS
19	Altered Insulin Secretory Responses to Glucose in Subjects with a Mutation in the MODY1 Gene on Chromosome 20. Diabetes, 1995, 44, 699-704.	0.6	132
20	Clinical Phenotypes, Insulin Secretion, and Insulin Sensitivity in Kindreds With Maternally Inherited Diabetes and Deafness Due to Mitochondrial tRNALeu(UUR) Gene Mutation. Diabetes, 1996, 45, 478-487.	0.6	121
21	Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus Journal of Clinical Investigation, 1993, 92, 262-271.	8.2	112
22	Entrainment of pulsatile insulin secretion by oscillatory glucose infusion Journal of Clinical Investigation, 1991, 87, 439-445.	8.2	95
23	Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations. Diabetologia, 1999, 42, 1314-1323.	6.3	90
24	Sleepiness, Performance, and Neuroendocrine Function during Sleep Deprivation: Effects of Exposure to Bright Light or Exercise. Journal of Biological Rhythms, 1997, 12, 245-258.	2.6	78
25	NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. European Journal of Pharmacology, 2002, 451, 217-225.	3.5	69
26	Failure of physiological plasma glucose excursions to entrain high-frequency pulsatile insulin secretion in type 2 diabetes. Diabetes, 2000, 49, 1334-1340.	0.6	66
27	Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. Diabetologia, 2002, 45, 49-55.	6.3	62
28	Dual PPARα/γ activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. American Journal of Physiology - Endocrinology and Metabolism, 2003, 284, E841-E854.	3.5	61
29	24-hour glucose profiles during continuous or oscillatory insulin infusion. Demonstration of the functional significance of ultradian insulin oscillations Journal of Clinical Investigation, 1995, 95, 1464-1471.	8.2	61
30	Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide. Pharmaceutical Research, 2019, 36, 49.	3.5	60
31	Abnormalities in the ultradian oscillations of insulin secretion and glucose levels in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia, 1992, 35, 681-689.	6.3	55
32	NN414, a SUR1/Kir6.2-Selective Potassium Channel Opener, Reduces Blood Glucose and Improves Glucose Tolerance in the VDF Zucker Rat. Diabetes, 2003, 52, 2513-2518.	0.6	49
33	Temporal Profiles and Clinical Significance of Pulsatile Insulin Secretion. Hormone Research in Paediatrics, 1998, 49, 178-184.	1.8	41
34	Alterations in the kinetics of C-peptide and insulin secretion in hyperthyroidism Journal of Clinical Endocrinology and Metabolism, 1993, 76, 79-84.	3.6	39
35	Abnormal temporal patterns of glucose tolerance in obesity: relationship to sleep-related growth hormone secretion and circadian cortisol rhythmicity Journal of Clinical Endocrinology and Metabolism, 1994, 79, 1797-1805.	3.6	39
36	Measurements of insulin responses as predictive markers of pancreatic β-cell mass in normal and β-cell-reduced lean and obese Göttingen minipigs in vivo. American Journal of Physiology - Endocrinology and Metabolism, 2006, 290, E670-E677.	3.5	36

JEPPE STURIS

#	Article	IF	CITATIONS
37	Oscillatory Insulin Secretion After Pancreas Transplant. Diabetes, 1993, 42, 855-861.	0.6	34
38	Phaseâ€locking regions in a forced model of slow insulin and glucose oscillations. Chaos, 1995, 5, 193-199.	2.5	34
39	Concordant induction of rapid in vivo pulsatile insulin secretion by recurrent punctuated glucose infusions. American Journal of Physiology - Endocrinology and Metabolism, 2000, 278, E162-E170.	3.5	33
40	GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: Selection of NN2211 for clinical development. Drugs of the Future, 2001, 26, 677.	0.1	32
41	Combination of the insulin sensitizer, pioglitazone, and the longâ€acting GLPâ€1 human analog, liraglutide, exerts potent synergistic glucoseâ€lowering efficacy in severely diabetic ZDF rats. Diabetes, Obesity and Metabolism, 2008, 10, 301-311.	4.4	31
42	Improved Â-Cell Survival and Reduced Insulitis in a Type 1 Diabetic Rat Model After Treatment With a Â-Cell-Selective KATP Channel Opener. Diabetes, 2004, 53, 1089-1095.	0.6	30
43	Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency. Diabetes Care, 2000, 23, 675-681.	8.6	29
44	Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor. Diabetes, Obesity and Metabolism, 2010, 12, 665-673.	4.4	27
45	High-frequency oscillations in circulating amylin concentrations in healthy humans. American Journal of Physiology - Endocrinology and Metabolism, 2000, 278, E484-E490.	3.5	26
46	Sensory nerve inactivation by resiniferatoxin improves insulin sensitivity in male obese Zucker rats. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E1137-E1145.	3.5	25
47	Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K+-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats. Metabolism: Clinical and Experimental, 2004, 53, 441-447.	3.4	23
48	Commemorating insulin's centennial: engineering insulin pharmacology towards physiology. Trends in Pharmacological Sciences, 2021, 42, 620-639.	8.7	22
49	Generic bifurcation structures of Arnol'd tongues in forced oscillators. Physical Review A, 1991, 44, 3503-3510.	2.5	20
50	Differential effects of glucose stimulation upon rapid pulses and ultradian oscillations of insulin secretion Journal of Clinical Endocrinology and Metabolism, 1993, 76, 895-901.	3.6	20
51	Explosion of limit cycles and chaotic waves in a simple nonlinear chemical system. Physical Review E, 2001, 64, 026209.	2.1	20
52	Acute hyperglycemia alters the ability of the normal β-cell to sense and respond to glucose. American Journal of Physiology - Endocrinology and Metabolism, 2002, 282, E917-E922.	3.5	20
53	Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes. Diabetic Medicine, 2005, 22, 1408-1413.	2.3	19
54	Alterations in the Patterns of Insulin Secretion Before and After Diagnosis of IDDM. Diabetes Care, 1995, 18, 568-571.	8.6	16

Jeppe Sturis

#	Article	IF	CITATIONS
55	Detecting functional relationships between simultaneous time series. Physical Review E, 2001, 64, 026221.	2.1	13
56	The conscious Göttingen minipig as a model for studying rapid pulsatile insulin secretion in vivo. Diabetologia, 2002, 45, 1389-1396.	6.3	13
57	Bifurcation sequence in a simple model of migratory dynamics. System Dynamics Review, 1988, 4, 208-217.	1.9	12
58	Synergistic effect of the human GLPâ€l analogue liraglutide and a dual PPARα/γ agonist on glycaemic control in Zucker diabetic fatty rats. Diabetes, Obesity and Metabolism, 2009, 11, 795-803.	4.4	12
59	Chaotic structures in generic management models: Pedagogical principles and examples. System Dynamics Review, 1988, 4, 218-245.	1.9	11
60	Local and global bifurcations in a model of the economic long wave. System Dynamics Review, 1991, 7, 41-60.	1.9	11
61	Beta-cell selective KATP-channel activation protects beta-cells and human islets from human islet amyloid polypeptide induced toxicity. Regulatory Peptides, 2010, 165, 158-162.	1.9	10
62	Acute Insulin Responses to Intravenous Glucose and GLP-1 are Independent of Preceding High-frequency Insulin Pulse-defects Induced by Glucose Entrainment in Healthy Humans. Hormone and Metabolic Research, 2005, 37, 40-44.	1.5	6
63	Pharmacokinetics and pharmacodynamics of different modes of insulin pump delivery. A randomized, controlled study comparing subcutaneous and intravenous administration of insulin aspart. Diabetic Medicine, 2011, 28, 230-236.	2.3	6
64	Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMedTM 670G hybrid closed-loop system in simulated trials compared to NovoLog®. Computer Methods and Programs in Biomedicine, 2021, 205, 106087.	4.7	6
65	Local and global bifurcations at infinity in models of glycolytic oscillations. Journal of Mathematical Biology, 1997, 36, 119-132.	1.9	5
66	HOMOCLINIC BIFURCATION TO INFINITY IN A MODEL OF THE ECONOMIC LONG WAVE. International Journal of Bifurcation and Chaos in Applied Sciences and Engineering, 1992, 02, 129-136.	1.7	3
67	Modelling Seasonal Predator-Prey Interactions. Journal of Theoretical Biology, 1996, 178, 99-103.	1.7	3
68	Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. Journal of Pharmacy and Pharmacology, 2012, 65, 230-235.	2.4	3
69	Hopf bifurcation analysis applied to predatorâ€prey modeling. System Dynamics Review, 1992, 8, 179-186.	1.9	2
70	CHAOS AND CHAOTIC TRANSIENTS IN A FORCED MODEL OF THE ECONOMIC LONG WAVE: THE ROLE OF HOMOCLINIC BIFURCATION TO INFINITY. International Journal of Bifurcation and Chaos in Applied Sciences and Engineering, 1995, 05, 741-749.	1.7	2
71	Explorative Study of Pharmacokinetics and Pharmacodynamics after Change in Basal Insulin Infusion Rate. Journal of Diabetes Science and Technology, 2011, 5, 120-128.	2.2	2
72	Continuous Glucose Monitoring Sensor Glucose Levels and Insulin Pump Infusion Set Wear-Time During Treatment with Fast-Acting Insulin Aspart: A Post Hoc Analysis of Onset 5. Diabetes Technology and Therapeutics, 2022, 24, 10-17.	4.4	2

#	Article	IF	CITATIONS
73	Irish endocrine society. Irish Journal of Medical Science, 1994, 163, 246-253.	1.5	0
74	Techniques for Assessing Ultradian Rhythms in Hormonal Secretion. Methods in Neurosciences, 1995, , 139-155.	0.5	0